More interestingly, recently, the Food and Drug Administration (FDA) provided an accelerated approval to the use of the ADC trastuzumab deruxtecan (T-DXd) in patients with previously treated, unresectable or metastatic NSCLC carrying activating Her2 mutations. Here, ERBB2 is linked to non-small cell lung carcinoma.